CRL Intrinsic Value Calculation – Adviser Investments LLC Invests in Charles River Laboratories International, Inc
December 23, 2023
🌥️Trending News
Adviser Investments LLC recently announced that it has invested in Charles River Laboratories ($NYSE:CRL) International, Inc. (CRVL). Charles River Laboratories is one of the world’s leading providers of preclinical services to the pharmaceutical, biotechnology, and medical device industries. The company specializes in safety assessments of new drugs, biologics and medical devices, providing research models and customized services for drug discovery and development. In addition, the company provides consulting services and laboratory testing services to support early-stage development.
Price History
Adviser Investments LLC recently made a significant investment in Charles River Laboratories International, Inc, which opened on Friday at $237.2 and closed at $236.2, up by 0.2% from its previous closing price of 235.7. This small but significant gain signals a promising future for the company, and Adviser Investments LLC is confident that their investment in Charles River Labs International will pay off in the long term. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for CRL. More…
| Total Revenues | Net Income | Net Margin |
| 4.22k | 474.95 | 11.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for CRL. More…
| Operations | Investing | Financing |
| 697.71 | -280.4 | -458.05 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for CRL. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 7.61k | 4.26k | 64.45 |
Key Ratios Snapshot
Some of the financial key ratios for CRL are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 14.3% | 16.2% | 17.9% |
| FCF Margin | ROE | ROA |
| 8.7% | 14.4% | 6.2% |
Analysis – CRL Intrinsic Value Calculation
At GoodWhale, we have conducted an analysis of CHARLES RIVER LABORATORIES INTERNATIONAL’s financials. After a thorough analysis, our proprietary Valuation Line has determined that the fair value of their stock is around $307.8. However, the stock is currently traded at $236.2, representing an undervaluation of 23.3%. This discrepancy offers an opportunity for investors to purchase the stock at a discounted price. More…
Peers
The global market for contract research services is growing rapidly as more and more companies are outsourcing their research and development needs. This growth is being driven by the increasing costs of R&D, the need for faster timelines, and the desire to tap into the expertise of experienced professionals. As the market expands, so does the competition, and Charles River Laboratories International Inc is up against some stiff competition from the likes of Microba Life Sciences Ltd, IDenta Corp, and Eurofins Scientific SE.
– Microba Life Sciences Ltd ($ASX:MAP)
Denta Corp is a publicly traded company that provides dental products and services. The company has a market capitalization of 1.5 million as of 2022 and a return on equity of -10.42%. The company’s products and services include dental implants, dentures, and other dental prosthetics. Denta Corp also provides dental education and training services. The company was founded in 2006 and is headquartered in New York, New York.
– IDenta Corp ($OTCPK:IDTA)
Eurofins Scientific SE is a global leader in the provision of analytical testing and scientific services. The company has a market capitalization of 13.54 billion as of 2022 and a return on equity of 12.32%. The company provides a range of services including food testing, environmental testing, pharmaceutical testing, and forensics. Eurofins Scientific SE has a network of over 800 laboratories across 47 countries.
Summary
Adviser Investments LLC recently announced that they have taken a position in Charles River Laboratories International, Inc. (CRL). CRL offer essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. CRL’s financials have been solid, with a strong balance sheet, earnings growth and cash flow.
Their financial performance along with their strong customer relationships and good business model has made CRL an attractive stock for investors. Analyst projections of future revenue and earnings growth give further assurance that this stock will continue to perform well and Adviser Investments LLC is confident that this stock offers long-term growth potential for investors.
